“For women with metastatic breast cancer we have many therapies available. Trastuzumab deruxtecan is a new option for a subgroup of patients who do not have a high expression of Her2, therefore non-Her2 positive tumors, for which we have a drug that has demonstrated to clinically and statistically significantly increase the survival of these women. Furthermore, this was done without a negative impact on the quality of life, indeed many parameters improved.” Thus Giampaolo Bianchini, associate professor and head of the Breast Group of the Irccs San Raffaele hospital, Vita-Salute San Raffaele University of Milan during an event, today in Milan, on early diagnosis and targeted therapies for Her2 low metastatic breast cancer.
The approval of the reimbursement by the AIFA of the monoclonal antibody drug-conjugate of Daiichi Sankyo and AstraZeneca “represents excellent news for patients – underlines Bianchini – because with this innovative drug we have a longer survival duration, it has increased the median survival of almost six months and the proportional risk of death is reduced by 36%, really important data. The risk of progression, i.e. that the therapy no longer works, is also reduced by almost 50%. Furthermore, if we think to the most common question that patients ask us, i.e. whether the tumor has regressed, we have almost 50% objective answers compared to 16%: three times more than what could be obtained with the previous therapy”.
Therefore “it is a really important therapeutic option and I underline again that this does not happen at the expense of greater toxicity. The data demonstrate that for many parameters the quality of life and time to clinical deterioration are significantly improved with this drug compared to previously available treatments,” he concludes.
#Bianchini #UniSr #39Her2 #metastatic #breast #cancer #therapy #excellent #news #patients39
